Wang M, Sun L, Han X, Ren J, et al. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy. Clin Res Hepatol Gastroenterol 2023;47:102060.
PMID: 36473631